Ken Griffin Alzamend Neuro, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Alzamend Neuro, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 400 shares of ALZN stock, worth $664. This represents 0.0% of its overall portfolio holdings.

Number of Shares
400
Holding current value
$664
% of portfolio
0.0%

Shares

0 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
No transaction found.

About Alzamend Neuro, Inc.

ALZN Quotes by TradingView
  • Ticker ALZN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 95,481,800
  • Market Cap $158M
  • Description
  • Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...
More about ALZN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email